Carisma Therapeutics Inc (NASDAQ:CARM)’s traded shares stood at 36.57 million during the last session, with the company’s beta value hitting 2.04. At the close of trading, the stock’s price was $0.60, to imply a decrease of -45.66% or -$0.51 in intraday trading. The CARM share’s 52-week high remains $1.90, putting it -216.67% down since that peak but still an impressive 76.67% since price per share fell to its 52-week low of $0.14.
Analysts have given a consensus recommendation of Buy for Carisma Therapeutics Inc (CARM), translating to a mean rating of 2.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give CARM a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy.
Carisma Therapeutics Inc (NASDAQ:CARM) trade information
After registering a -45.66% downside in the last session, Carisma Therapeutics Inc (CARM) has traded red over the past five days. The 5-day price performance for the stock is 242.73%, and 212.54% over 30 days. With these gigs, the year-to-date price performance is 44.03%.
The extremes give us $6 and $6 for target low and target high price respectively. As such, CARM has been trading -900.0% off suggested target high and -900.0% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 42.71% for the past 5-year period. While 2025 is set for a 50.00% return in earnings, projections for the next 5 years are at 24.74% annually.
CARM Dividends
Carisma Therapeutics Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA with 1.25 million shares, or about 3.014% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.9 million.
